darunavir/cobicistat (Rezolsta®)

Reference No. 2193

Publication date:

02/09/2015

Appraisal information

darunavir/cobicistat (Rezolsta®) 800 mg/150 mg film-coated tablet

Company:	Janssen-Cilag Ltd
BNF category:	Infections
NMG meeting date:	10/06/2015
AWMSG meeting date:	15/07/2015

Submission Type:	Full Submission
Status:	Recommended
Advice No:	2115
Ministerial ratification:	27/08/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Darunavir/cobicistat (Rezolsta®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.

Final Appraisal Recommendation (FAR)

Download

darunavir-cobicistat (Rezolsta) 2193 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

darunavir-cobicistat (Rezolsta) 2193 ASAR

Clinical Expert (CE) Summary

Download

darunavir-cobicistat (Rezolsta) 2193 CE summary